このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Evotec バランスシートの健全性

財務の健全性基準チェック /36

Evotecの総株主資本は€1.1B 、総負債は€627.6Mで、負債比率は56.7%となります。総資産と総負債はそれぞれ€2.2Bと€1.1Bです。

主要情報

56.7%

負債資本比率

€627.55m

負債

インタレスト・カバレッジ・レシオ	n/a
現金	€509.94m
エクイティ	€1.11b
負債合計	€1.10b
総資産	€2.21b

財務の健全性に関する最新情報

Recent updates

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Apr 10

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Mar 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Jan 09

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Oct 05

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Jun 28

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

May 14

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Feb 25

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Jul 29

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

May 16

Is Evotec (ETR:EVT) A Risky Investment?

Apr 28

Do Evotec's (ETR:EVT) Earnings Warrant Your Attention?

Mar 15

At €36.91, Is It Time To Put Evotec SE (ETR:EVT) On Your Watch List?

Jan 10

Evotec (ETR:EVT) Takes On Some Risk With Its Use Of Debt

Nov 14

Is It Time To Consider Buying Evotec SE (ETR:EVT)?

Oct 10

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Aug 16

Is It Time To Consider Buying Evotec SE (ETR:EVT)?

Jul 03

Evotec SE's (ETR:EVT) CEO Looks Due For A Compensation Raise

Jun 07

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Apr 30

財務状況分析

短期負債: EVTの短期資産 ( €826.1M ) が短期負債 ( €443.0M ) を超えています。

長期負債: EVTの短期資産 ( €826.1M ) が長期負債 ( €659.1M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: EVTの純負債対資本比率 ( 10.6% ) は満足できる水準であると考えられます。

負債の削減: EVTの負債対資本比率は、過去 5 年間で27.4%から56.7%に増加しました。

債務返済能力: EVTの営業キャッシュフローはマイナスであるため、負債は十分にカバーされていません。

インタレストカバレッジ: EVTの負債に対する利息支払いが EBIT によって十分にカバーされているかどうかを判断するにはデータが不十分です。

Evotec バランスシートの健全性

財務の健全性 基準チェック /36

主要情報

財務の健全性に関する最新情報

Evotec SE announced delayed 20-F filing

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Recent updates

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec Se Provides Revenue Guidance for 2022

Consensus forecasts updated

Do Evotec's (ETR:EVT) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

At €36.91, Is It Time To Put Evotec SE (ETR:EVT) On Your Watch List?

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

財務の健全性基準チェック /36